AR061064A1 - Inhibicion mediada por arni de afecciones relacionadas con el factor de necrosis tumoral alfa - Google Patents
Inhibicion mediada por arni de afecciones relacionadas con el factor de necrosis tumoral alfaInfo
- Publication number
- AR061064A1 AR061064A1 ARP070102199A ARP070102199A AR061064A1 AR 061064 A1 AR061064 A1 AR 061064A1 AR P070102199 A ARP070102199 A AR P070102199A AR P070102199 A ARP070102199 A AR P070102199A AR 061064 A1 AR061064 A1 AR 061064A1
- Authority
- AR
- Argentina
- Prior art keywords
- sec
- tnfalfa
- mrna
- silencing
- composition
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 241000320892 Clerodendrum phlomidis Species 0.000 title 1
- 229940125365 angiotensin receptor blocker-neprilysin inhibitor Drugs 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 abstract 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 230000030279 gene silencing Effects 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 108091007505 ADAM17 Proteins 0.000 abstract 1
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Se proporciona una interferencia de ARN para la inhibicion del factor de necrosis tumoral alfa (TNFalfa) silenciando la expresion del ARNm del receptor de superficie celular del TNFalfa, receptor 1 del TNF (TNFR1), o silenciando la expresion del ARNm de la enzima conversora del TNFalfa (TACE/ADAM17). El silenciamiento de dichos blancos del TNFalfa, en particular, es util para tratar pacientes que padecen una afeccion relacionada con el TNFalfa o en riesgo de desarrollar una afeccion relacionada con el TNFalfa, tal como las afecciones oculares de ojo seco, conjuntivitis alérgica o inflamacion ocular, o tales como dermatitis, rinitis o asma, por ejemplo. Reivindicacion 39: Una composicion que comprende un ARN de interferencia con una longitud de 19 a 49 nucleotidos, y que comprende una secuencia de nucleotidos correspondiente a cualquiera de SEC. ID N°:3, SEC. ID N°:14 - SEC. ID N°:58, y SEC. ID N°:155-SEC. ID N°:201, o un complemento de ella; y un portador farmacéuticamente aceptable. Reivindicacion 40: Una composicion que comprende un ARN de interferencia que consiste esencialmente en una secuencia de nucleotidos correspondiente a cualquiera de SEC. ID N°:59 - SEC. ID N°:69, SEC. ID N°:71 - SEC. ID N°:92, y SEC. ID N°:94 - SEC. ID N°:154, o un complemento de ella; y un portador farmacéuticamente aceptable. Reivindicacion 41: La composicion de la reivindicacion 39, en donde el ARN de interferencia es uno de un ARNsh, un ARNsi o un ARNmi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80178806P | 2006-05-19 | 2006-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061064A1 true AR061064A1 (es) | 2008-07-30 |
Family
ID=38702032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102199A AR061064A1 (es) | 2006-05-19 | 2007-05-21 | Inhibicion mediada por arni de afecciones relacionadas con el factor de necrosis tumoral alfa |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7732421B2 (es) |
| EP (1) | EP2018426B1 (es) |
| JP (4) | JP2009537566A (es) |
| KR (2) | KR20120093306A (es) |
| CN (2) | CN101448943B (es) |
| AR (1) | AR061064A1 (es) |
| AU (1) | AU2007253776B2 (es) |
| CA (1) | CA2650416A1 (es) |
| CL (2) | CL2007001434A1 (es) |
| ES (1) | ES2413804T3 (es) |
| MX (1) | MX2008014260A (es) |
| PL (1) | PL2018426T3 (es) |
| RU (1) | RU2469090C2 (es) |
| TW (1) | TWI472344B (es) |
| UY (1) | UY30361A1 (es) |
| WO (1) | WO2007137129A2 (es) |
| ZA (1) | ZA200809203B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| KR20120093306A (ko) * | 2006-05-19 | 2012-08-22 | 알콘 리서치, 리미티드 | 종양 괴사 인자 α-관련 증상의 ＲＮＡｉ-매개 억제 |
| CA2672961A1 (en) * | 2006-12-19 | 2008-07-10 | Danute Bankaitis-Davis | Gene expression profiling for identification, monitoring, and treatment of ocular disease |
| GB0708662D0 (en) * | 2007-05-04 | 2007-06-13 | Galapagos Nv | shRNA sequences |
| PT2170403E (pt) | 2007-06-27 | 2014-07-17 | Quark Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes pró-apoptóticos |
| CL2008002278A1 (es) * | 2007-08-03 | 2009-07-17 | Alcon Res Ltd | Metodo para el tratamiento de una enfermedad ocular relacionada al tnfalfa; metodo para la atenuacion de la expresion del arnm de tace o tnfr1 en el ojo de un paciente. |
| US20090036396A1 (en) | 2007-08-03 | 2009-02-05 | Alcon Research, Ltd. | RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS |
| KR20100061792A (ko) * | 2007-10-01 | 2010-06-09 | 알콘 리서치, 리미티드 | 안 질환을 치료 또는 예방하기 위한 간섭 ｒｎａ 분자의 자기-상보적 ａａｖ 매개 전달 |
| WO2009052140A1 (en) * | 2007-10-15 | 2009-04-23 | Alcon Research, Ltd. | Use of tnf receptor antagonists for treating dry eye |
| CN102178959B (zh) * | 2011-03-15 | 2013-10-23 | 清华大学深圳研究生院 | 抑制肺转移肿瘤生长的siRNA及其寡聚核酸组合与应用 |
| EP2746396A1 (en) * | 2012-12-20 | 2014-06-25 | PLS-Design GmbH | Selective local inhibition of TNFR1-mediated functions at the site of antigen/allergen presentation |
| WO2014169264A2 (en) | 2013-04-11 | 2014-10-16 | The Board Of Trustees Of The University Of Illinois | Nanoparticle mediated delivery of sirna |
| CN104560997B (zh) * | 2014-12-25 | 2018-05-04 | 中国科学院广州生物医药与健康研究院 | 抑制ADAMTS-5和ADAM17基因的siRNA组合物及其应用 |
| CN104498498A (zh) * | 2014-12-25 | 2015-04-08 | 广州市锐博生物科技有限公司 | 抑制ADAM17基因的siRNA及其应用 |
| ES2833028T3 (es) | 2014-12-25 | 2021-06-14 | Guangzhou Ribobio Co Ltd | Composiciones y métodos para inhibir la expresión de ADAMTS-5 y ADAM17 |
| CN104560999B (zh) * | 2014-12-25 | 2018-01-09 | 广州市锐博生物科技有限公司 | 抑制ADAMTS‑5基因的siRNA及其应用 |
| CN105349502A (zh) * | 2015-12-09 | 2016-02-24 | 山西医科大学 | Tnfr1基因重组腺病毒及其构建 |
| KR102692717B1 (ko) * | 2016-09-23 | 2024-08-08 | (주)아모레퍼시픽 | Tnfrsf14 억제 물질을 포함하는 피부 미백용 조성물 및 tnfrsf14 억제 물질의 스크리닝 방법 |
| US10709793B2 (en) | 2016-09-30 | 2020-07-14 | Industry-University Cooperation Foundation Hanyang University | Gene/carrier complex for preventing or treating inflammatory diseases |
| WO2018140613A1 (en) | 2017-01-25 | 2018-08-02 | The Board Of Trustees Of The University Of Illinois | Conformation switchable antimicrobial peptides and methods of using the same |
| AU2018338100A1 (en) | 2017-09-22 | 2020-04-09 | John Mansell | Compositions and methods for treatment of sepsis-related disorders |
| KR102163667B1 (ko) * | 2018-03-27 | 2020-10-08 | 한양대학교 산학협력단 | 염증성 질환 예방 또는 치료용 유전자／전달체 복합체 |
| CN114410627B (zh) * | 2021-12-20 | 2023-08-08 | 硅羿科技（上海）有限公司 | 一种特异性敲降TNF-α基因表达的siRNA及其应用 |
| US20250075209A1 (en) * | 2021-12-27 | 2025-03-06 | Apellis Pharmaceuticals, Inc. | Rnas for complement inhibition |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180403B1 (en) * | 1999-10-28 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| AU1521000A (en) * | 1998-11-06 | 2000-05-29 | Schepens Eye Research Institute, Inc., The | Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye |
| US6632667B1 (en) * | 1999-10-28 | 2003-10-14 | Isis Pharmaceuticals, Inc. | Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE) |
| WO2002048168A1 (en) * | 2000-10-24 | 2002-06-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of tnfr1 expression |
| US20050227935A1 (en) | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
| CN1239161C (zh) * | 2001-05-21 | 2006-02-01 | 爱尔康公司 | 可用于治疗干眼疾病的类固醇 |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| EP1576007A2 (en) * | 2002-12-23 | 2005-09-21 | Ingenium Pharmaceuticals AG | Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders |
| US8110674B2 (en) * | 2003-03-07 | 2012-02-07 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
| WO2004113387A2 (en) * | 2003-06-24 | 2004-12-29 | Merck Patent Gmbh | Tumour necrosis factor receptor molecules with reduced immunogenicity |
| WO2005076998A2 (en) * | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| ATE524546T1 (de) * | 2005-03-25 | 2011-09-15 | Medtronic Inc | Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung |
| KR20120093306A (ko) * | 2006-05-19 | 2012-08-22 | 알콘 리서치, 리미티드 | 종양 괴사 인자 α-관련 증상의 ＲＮＡｉ-매개 억제 |
| WO2009052140A1 (en) * | 2007-10-15 | 2009-04-23 | Alcon Research, Ltd. | Use of tnf receptor antagonists for treating dry eye |
-
2007
- 2007-05-17 KR KR1020127013309A patent/KR20120093306A/ko not_active Ceased
- 2007-05-17 CN CN2007800177777A patent/CN101448943B/zh not_active Expired - Fee Related
- 2007-05-17 ES ES07797553T patent/ES2413804T3/es active Active
- 2007-05-17 AU AU2007253776A patent/AU2007253776B2/en not_active Ceased
- 2007-05-17 MX MX2008014260A patent/MX2008014260A/es active IP Right Grant
- 2007-05-17 RU RU2008150324/10A patent/RU2469090C2/ru not_active IP Right Cessation
- 2007-05-17 EP EP07797553.0A patent/EP2018426B1/en not_active Not-in-force
- 2007-05-17 CA CA002650416A patent/CA2650416A1/en not_active Abandoned
- 2007-05-17 CN CN201310233381.3A patent/CN103285026B/zh not_active Expired - Fee Related
- 2007-05-17 KR KR1020087030030A patent/KR20090010234A/ko not_active Ceased
- 2007-05-17 JP JP2009511237A patent/JP2009537566A/ja not_active Withdrawn
- 2007-05-17 WO PCT/US2007/069165 patent/WO2007137129A2/en not_active Ceased
- 2007-05-17 US US11/750,262 patent/US7732421B2/en active Active
- 2007-05-17 PL PL07797553T patent/PL2018426T3/pl unknown
- 2007-05-18 CL CL200701434A patent/CL2007001434A1/es unknown
- 2007-05-18 TW TW96117872A patent/TWI472344B/zh not_active IP Right Cessation
- 2007-05-21 AR ARP070102199A patent/AR061064A1/es unknown
- 2007-05-22 UY UY30361A patent/UY30361A1/es not_active Application Discontinuation
-
2008
- 2008-10-27 ZA ZA2008/09203A patent/ZA200809203B/en unknown
-
2010
- 2010-02-04 US US12/700,188 patent/US20100166676A1/en not_active Abandoned
- 2010-10-08 CL CL2010001109A patent/CL2010001109A1/es unknown
-
2011
- 2011-02-25 US US13/035,147 patent/US8541389B2/en not_active Expired - Fee Related
-
2012
- 2012-12-11 JP JP2012270348A patent/JP2013049728A/ja not_active Withdrawn
- 2012-12-11 JP JP2012270347A patent/JP2013049727A/ja not_active Withdrawn
-
2013
- 2013-08-22 US US13/973,176 patent/US20130338213A1/en not_active Abandoned
-
2014
- 2014-04-03 US US14/244,623 patent/US9447419B2/en active Active
-
2015
- 2015-11-27 JP JP2015231338A patent/JP2016033153A/ja active Pending
-
2016
- 2016-09-02 US US15/255,372 patent/US20160369283A1/en not_active Abandoned
-
2018
- 2018-10-11 US US16/157,726 patent/US20190032061A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061064A1 (es) | Inhibicion mediada por arni de afecciones relacionadas con el factor de necrosis tumoral alfa | |
| Kapetanaki et al. | Influence of age on wound healing and fibrosis | |
| Xu et al. | MEG3/miR-21 axis affects cell mobility by suppressing epithelial-mesenchymal transition in gastric cancer | |
| Liu et al. | MiR‐155 inhibits cell migration of human cardiomyocyte progenitor cells (hCMPC s) via targeting of MMP‐16 | |
| Han et al. | The macro domain protein family: structure, functions, and their potential therapeutic implications | |
| Miao et al. | MicroRNA-152 modulates the canonical Wnt pathway activation by targeting DNA methyltransferase 1 in arthritic rat model | |
| Zhao et al. | Differential expression of microRNAs in decidua-derived mesenchymal stem cells from patients with pre-eclampsia | |
| Li et al. | Roles of miR-1-1 and miR-181c in ventricular septal defects | |
| Dhawan et al. | A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability | |
| Feng et al. | miR-141-3p inhibits fibroblast proliferation and migration by targeting GAB1 in keloids | |
| BRPI0715176A8 (pt) | compostos de heteroarila utéis como inibidores de enzimas de ativação e1 | |
| BR112012014760A2 (pt) | "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso" | |
| AR081450A1 (es) | Tratamiento de sarcoidosis usando celulas madre de placenta | |
| Borrás et al. | Centenarians maintain miRNA biogenesis pathway while it is impaired in octogenarians | |
| CO6190565A2 (es) | Aptameros, metodos para su seleccion y usos | |
| Jin et al. | Adipose-derived stem cells suppress inflammation induced by IL-1β through down-regulation of P2X7R mediated by miR-373 in chondrocytes of osteoarthritis | |
| ECSP099061A (es) | Moduladores de benzofuro- y benzotienopirimidina | |
| CL2011002461A1 (es) | Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica. | |
| AR060448A1 (es) | Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo | |
| CL2013000893A1 (es) | Medio para cultivo de celulas de mamiferos que comprende sobrenadante de la etapa i del fraccionamiento de cohn; procedimiento de preparacion del medio; uso del medio de cultivo para cultivar celulas de mamiferos. | |
| Zhang et al. | An integrated study of natural hydroxyapatite-induced osteogenic differentiation of mesenchymal stem cells using transcriptomics, proteomics and microRNA analyses | |
| Liu et al. | Downregulated microRNA‑133a induces HUVECs injury: Potential role of the (pro) renin receptor in angiotensin II‑dependent hypertension | |
| Liu et al. | Serum extracellular vesicles promote proliferation of H9C2 cardiomyocytes by increasing miR-17-3p | |
| Yang et al. | CircPTTG1IP knockdown suppresses rheumatoid arthritis progression by targeting miR-431-5p/FSTL1 axis | |
| CL2011002618A1 (es) | Compuestos derivados de arilsulfonamidas 2,5-disustituidas; composición farmacéutica que los comprende; y uso del compuesto o de la composición como moduladores de ccr3 para prevenir o tratar una enfermedad inflamatoria tal como asma, asma inducido por ejercicio, rinitis alérgica, dermatitis atópica, conjuntivitis alérgica o enfermedad obstructiva crónica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |